Expanding Access to AID
with Omnipod® 5
Hosted by Nancy Hanna
This episode features Dr. Aleppo, an endocrinologist, who has a commercial relationship with Insulet and was compensated for her participation in the podcast.
Dr. Grazia Aleppo returns to Beyond the Bolus to share her insights from ADA 2025 and beyond. In this engaging conversation, Dr. Aleppo discusses the evolution of automated insulin delivery (AID) systems, the RADIANT and SECURE-T2D clinical trials, and why Omnipod® 5 is changing the game for people with both type 1 and type 2 diabetes. From helping patients to overcome fears of hypoglycemia to simplifying care, Dr. Aleppo emphasizes the importance of challenging outdated assumptions about who benefits from AID and underscores the need for simple, more adaptable solutions for every patient.
Time stamps
5:06 – Insights from the RADIANT trial: Why patients with high A1C are ideal candidates for AID systems
09:48 – Dr. Aleppo shares a powerful patient story about overcoming fear of hypoglycemia and finally sleeping through the night
10:59 – How Omnipod 5 makes AID accessible for people with type 2 diabetes
27:00 – Practical optimization tips for insulin-to-carb ratios and correction factors to improve outcomes1
1. Retrospective RWE data on file. 2025. Results from users with optimized settings including sufficient CGM data (≥75% of days with ≥220 readings), ≥90% time in Automated Mode, ≥3 bolus/day and an average Target Glucose of 110-115 mg/dL. Optimized settings: ISF x TDI ≤1500, I:C Ratio x TDI ≤350. RF-062025-00014
The Omnipod 5 Automated Insulin Delivery System is a single hormone insulin delivery system intended to deliver U-100 insulin subcutaneously for the management of type 1 diabetes in persons aged 2 and older and type 2 diabetes in persons aged 18 and older. Rx only. WARNING: Do not use SmartAdjust™ technology for people under the age of 2 or who require less than 5 U of insulin per day. Visit omnipod.com/safety for complete safety information.